Celiac.com Sponsor (A1):



Celiac.com Sponsor (A1):


0
Scott Adams

Celiac Vaccine Clears First Big Clinical Trial

Rate this topic

Recommended Posts

syringe--red--cc--andres_rueda.jpg

Massachusetts biotech firm ImmusanT has announced the successful completion of its first phase 1b trial of Nexvax2, an immunotherapy drug designed to protect celiac sufferers from the adverse effects of gluten exposure, including gastrointestinal symptoms, such as diarrhea, abdominal pain and bloating.

Nexvax2 is a drug that relies on three peptides designed to promote T cells involved in the inflammatory reaction in celiac disease to become tolerant to gluten.

The company hopes that an initial course will promote gluten-tolerance, which can then be maintained by periodic boosters of the vaccine.

View the full article


Scott Adams

Celiac.com - Celiac Disease Board Moderator

Founder Celiac.com

Share this post


Link to post
Share on other sites

Join eNewsletter


Celiac.com Sponsor (A8):

Celiac.com Sponsor (A8):


Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

0


Join eNewsletter